Patents by Inventor Weng Chan

Weng Chan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adaptive text input modes for mobile electronic device
    Publication number: 20070257888
    Abstract: Adaptive text input modes for a mobile electronic device permit efficient entry of hybrid alpha-numeric text records, such as street addresses and calendar dates, using a keypad. Adaptive text input modes automatically toggle between different text input modes in a manner that conforms to expected formats for text records. The number of keypad inputs is thereby reduced without the need for a user of the mobile electronic device to manually toggle between text input modes when entering text records on the keypad. The adaptive text input modes may be selected based on location information.
    Type: Application
    Filed: May 3, 2006
    Publication date: November 8, 2007
    Inventor: Weng Chan
  • P21 derived peptides and uses thereof
    Publication number: 20060293245
    Abstract: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.
    Type: Application
    Filed: April 20, 2006
    Publication date: December 28, 2006
    Applicant: Cyclacel Limited
    Inventors: Daniella Zheleva, Peter Fischer, Campbell McInnes, Martin Andrews, Weng Chan, Gail Atkinson
  • p21 peptides
    Publication number: 20050153894
    Abstract: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.
    Type: Application
    Filed: April 13, 2004
    Publication date: July 14, 2005
    Applicant: Cyclacel Limited
    Inventors: Daniella Zheleva, Peter Fischer, Campbell Mclnnes, Martin Andrews, Weng Chan, Gail Atkinson